Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | PYGM | P11217 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15414301 | 1.00 | SCN9A (0.54) | SCN9AIDO1CCKARCCKBRCACNA1C | |
| SCHEMBL15414247 | 0.92 | SCN9A (0.54) | SCN9AIDO1CCKARCCKBRCACNA1C | |
| SCHEMBL9025396 | 0.91 | SCN9A (0.53) | SCN9AIDO1CCKARCCKBRCACNA1C | |
| SCHEMBL9025761 | 0.90 | SCN9A (0.68) | SCN9ACCKARCCKBR | |
| SCHEMBL29481025 | 0.87 | PYGL (0.50) | SCN9AIDO1CACNA1CPYGLPYGM | |
| SCHEMBL9023683 | 0.87 | ACE (0.52) | SCN9AIDO1CCKARCCKBRCACNA1C | |
| SCHEMBL15414268 | 0.85 | SCN9A (0.47) | SCN9AIDO1PYGLPYGM | |
| SCHEMBL15414265 | 0.85 | SCN9A (0.47) | SCN9AIDO1PYGLPYGM | |
| SCHEMBL1269800 | 0.85 | SCN9A (0.69) | SCN9ACACNA1C | |
| SCHEMBL4459388 | 0.85 | SCN9A (0.69) | SCN9ACACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872490-B1 | ANTIPROLIFERATIVE BENZO[B]AZEPIN-2-ONES | HOFFMANN LA ROCHE (CH) | 2018-02-07 | — | — | EP | disclosed |
| US-9611224-B2 | Antiproliferative benzo [B] azepin-2-ones | HOFFMANN-LA ROCHE INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150353499-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2872490-A1 | ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009495-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353499-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES | CCNY, RB1, TOP2B | SCN9A 4783/4885IDO1 2508/4885CCKAR 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.